SCHEMBL5657121

SCHEMBL5657121

COC(=O)c1cc(OC)c(OC)c2oc(Cc3ccc(OC)cc3)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ATM Q13315 1/20 0.43
SLC22A12 Q96S37 1/20 0.43
KDM4E B2RXH2 5/20 0.42
POLB P06746 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
TUBB4A P04350 2/20 0.41
TUBB P07437 2/20 0.41
TUBA3C P0DPH7 2/20 0.41
TUBA1B P68363 2/20 0.41
TUBA4A P68366 2/20 0.41
TUBB4B P68371 2/20 0.41
TUBB3 Q13509 2/20 0.41
TUBB2A Q13885 2/20 0.41
TUBB8 Q3ZCM7 2/20 0.41
TUBA3E Q6PEY2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5659101 0.90 SMN1; SMN2 (0.46) KDM4EPOLBALDH1A1LMNACNR2
SCHEMBL5657720 0.89 KDM4E (0.46) KDM4EPOLBALDH1A1HPGDCNR2
SCHEMBL5659291 0.88 MEN1 (0.41) MEN1KMT2AATMSLC22A12KDM4E
SCHEMBL5657737 0.88 PDE4B (0.46) MEN1KMT2AKDM4EPOLBALDH1A1
SCHEMBL5658511 0.81 MAPT (0.54) MEN1KMT2ASLC22A12KDM4EPOLB
SCHEMBL5658621 0.81 KDM4E (0.49) KDM4EPOLBALDH1A1HPGDUSP2
SCHEMBL5659220 0.81 TUBB4A (0.43) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5657441 0.81 TUBB1 (0.43) KDM4EPOLBALDH1A1TUBB4ATUBB
SCHEMBL5655596 0.80 KDM4E (0.48) MEN1KMT2AKDM4EPOLBALDH1A1
SCHEMBL5659653 0.78 PDE4A (0.50) MEN1KMT2AKDM4EPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030130-B2 Benzofuran derivatives and their use as antibacterial agents ARPIDA AG (CH) 2006-04-18 US disclosed
EP-1307445-B1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2005-12-21 EP disclosed
US-20040034047-A1 Benzofuran derivatives and their use as antibacterial agents EVOLVA SA (CH) 2004-02-19 US disclosed
EP-1307445-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS Arpida AG, (CH) 2003-05-07 EP disclosed
WO-2002010157-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034047-A1 Benzofuran derivatives and their use as antibacterial agents SBDS, BPTF, DCXR MEN1 4413/4885KMT2A 3563/4885ATM 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.